About us
Strominnate Therapeutics is a spinoff of Lund University, pioneering the development of a new era for treating tumors and conditions of the nervous system. Founded in 2021 we are now in an exciting development phase. We have an excellent team covering the essential expertise to bring this product to the market.
We have attracted over 1.8 MSEK, coming from soft money from competitive grants for entrepreneurship related to Lund University and from investors.
CEO Founder
Tania Ramos Moreno
PhD in Neuroscience. Researcher, educator & Entrepreneur.
Tania Ramos-Moreno is founder and CEO of Strominnate Therapeutics AB, and currently a guest researcher at the Stem Cell Center in Lund University.
She holds a PhD in Neuroscience and brings an extensive background on cell and gene therapies for treating disease and tumor in the central nervous system (CNS).
She has characterized and discovered the immune cell that the company uses for treating brain tumors, and brings experience on leading international groups in diverse academic environments.
Inventor and holder of the patent behind the company, she has also been obtaining funds from a diverse scope of funding agencies.
Board member, Investor
Eddie Thordarson
LU Holding PhD in Chemistry. Management and business development in the medtech- and pharmaceutical industries.
Eddie Thordarson holds a PhD in Chemistry and is a portfolio manager at LU Holding with 20 years of management and business development in the medtech- and pharmaceutical industries.
Among other positions, Eddie was the CEO of Magle Chemoswed and COO at A1M Pharma. Eddie chairs Strominnate Therapeutics AB’s board and assists the CEO in growing the company and board, and with financing its operation.
Board member
Anna Löfgren
Head of Global Quality. Quality Control
Anna Löfgren serves as Vice President and Head of Global Quality at Hansa Biopharma, a role she assumed in January 2025. In this position, she leads all aspects of global quality assurance and quality systems for biologics and immunotherapies, ensuring full compliance with GxP and regulatory standards in multiple international markets.
She holds board membership in VILDA, a leading Swedish network empowering women in life sciences leadership, where she mentors and promotes gender diversity at the executive level.
Board member
Christopher Bravery
Regulatory Consultant on Advanced Biologicals - Regulatory Affairs + CMC
Christopher Bravery is an experienced regulatory scientist with over 15 years of expertise in advanced therapy medicinal products (ATMPs), including cell and gene therapies. He joined Strominnate Therapeutics AB as an independent board member in September 2023, strengthening the leadership team with deep regulatory and strategic insight.
Christopher founded and currently leads Consulting on Advanced Biologicals Ltd (Advbiols) in London, UK, where he advises on regulatory strategy, quality (CMC), preclinical planning, and marketing authorisation for novel biologics and ATMPs.
Board member
Julio Enriquez Perez
Medical doctor & PhD in Neurosurgery. Founder and board member of medical supply company and an organic food company.
Julio Enríquez obtained his MD degree at the International University of Ecuador and his PhD in Clinical Medicine, Neurosurgery, at Lund University. His main research interests are the tumor microenvironment, tumor immunology and immunotherapies, with focus on malignant brain tumors.
He is currently tjänstgöring at Skåne University Hospitals.
Julio is also a founder and board member of SmartScience, a medical supply company, and of La Martha, an organic agriculture company, both in Ecuador.